Comi, G <br/><br/>
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.  [electronic resource] 

 -  Multiple sclerosis (Houndmills, Basingstoke, England)  Nov 2010 
 - 1360-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1477-0970 
<br/><br/><label>Standard No.: </label>10.1177/1352458510378127  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Brain--drug effects<br/>Disability Evaluation<br/>Double-Blind Method<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Magnetic Resonance Imaging<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Quinolones--administration & dosage